Clinical analysis and outcomes of amyotrophic lateral sclerosis with demyelinating polyneuropathy

被引:8
|
作者
Sawa, Nobuhiro [1 ]
Kataoka, Hiroshi [1 ]
Sugie, Kazuma [1 ]
Kawahara, Makoto [1 ]
Horikawa, Hirosei [1 ]
Kusunoki, Susumu [2 ]
Ueno, Satoshi [1 ]
机构
[1] Nara Med Univ, Dept Neurol, Kashihara, Nara 6348522, Japan
[2] Kinki Univ, Sch Med, Dept Neurol, Osaka 589, Japan
来源
AMYOTROPHIC LATERAL SCLEROSIS | 2012年 / 13卷 / 01期
关键词
Amyotrophic lateral sclerosis; sensory symptom; demyelinating neuropathy; polyneuropathy; prognosis; DIABETES-MELLITUS; ALS; NEUROPATHY; ANTIBODIES; CONDUCTION; DIAGNOSIS; CRITERIA; GD1A;
D O I
10.3109/17482968.2011.627590
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Abnormalities of both motor and sensory nerve action potentials, similar to those found in demyelinating polyneuropathy, may occur in patients with amyotrophic lateral sclerosis (ALS). We analyzed the clinical features of unusual ALS patients with demyelinating polyneuropathy (DPN) to delineate the characteristics and outcomes of this rare condition. We reviewed three ALS patients with DPN who were confirmed to meet the electrophysiological nerve conduction criteria for DPN among 157 patients with ALS. At the initial neurological examination, one patient had both subjective sensory symptoms and abnormal results of sensory examinations, and one patient had sensory symptoms. Motor weakness of the limbs was present in all patients, and fasciculation was present in two patients. Anti-GalNAc-GD1a IgG antibodies were evident in one. Sural nerve biopsy showed a moderate, marginal reduction in myelin thickness, and teased fiber analysis revealed segmental demyelination and remyelination, but axonal degeneration was found in one patient. The mean interval from disease onset to respiratory failure or death in our three patients and seven previously documented ALS patients with DPN was 43.1 +/- 18.7 months. Our findings suggest that survival in ALS with DPN is similar to that in classic ALS.
引用
收藏
页码:125 / 131
页数:7
相关论文
共 50 条
  • [31] Clinical studies of riluzole in amyotrophic lateral sclerosis
    Desai, J
    Swash, M
    DRUGS OF TODAY, 1997, 33 (08) : 595 - 600
  • [32] CLINICAL-FEATURES OF AMYOTROPHIC LATERAL SCLEROSIS
    DAVID, P
    LOMONACO, M
    PALIERI, G
    SCOPPETTA, C
    SERVIDEI, S
    TONALI, P
    VACCARIO, ML
    ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1981, 2 (02): : 113 - 117
  • [33] MRI and clinical features in amyotrophic lateral sclerosis
    M. Waragai
    Neuroradiology, 1997, 39 : 847 - 851
  • [34] Clinical presentation and diagnosis of Amyotrophic Lateral Sclerosis
    Ferguson, Toby A.
    Elman, Lauren B.
    NEUROREHABILITATION, 2007, 22 (06) : 409 - 416
  • [35] Current clinical trials in amyotrophic lateral sclerosis
    Bhatt, Jaydeep M.
    Gordon, Paul H.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (08) : 1197 - 1207
  • [36] Clinical diagnosis and management of amyotrophic lateral sclerosis
    Hardiman, Orla
    van den Berg, Leonard H.
    Kiernan, Matthew C.
    NATURE REVIEWS NEUROLOGY, 2011, 7 (11) : 639 - 649
  • [37] Amyotrophic lateral sclerosis: update on clinical management
    Norris, Simone P.
    Likanje, Marie-France N.
    Andrews, Jinsy A.
    CURRENT OPINION IN NEUROLOGY, 2020, 33 (05) : 641 - 648
  • [38] A clinical trial of dextromethorphan in amyotrophic lateral sclerosis
    Gredal, O
    Werdelin, L
    Bak, S
    Christensen, PB
    Boysen, G
    Kristensen, MO
    Jespersen, JH
    Regeur, L
    Hinge, HH
    Jensen, TS
    ACTA NEUROLOGICA SCANDINAVICA, 1997, 96 (01): : 8 - 13
  • [39] Advances in clinical trials for amyotrophic lateral sclerosis
    Gordon P.H.
    Current Neurology and Neuroscience Reports, 2005, 5 (1) : 48 - 54
  • [40] Clinical diagnosis and management of amyotrophic lateral sclerosis
    Orla Hardiman
    Leonard H. van den Berg
    Matthew C. Kiernan
    Nature Reviews Neurology, 2011, 7 : 639 - 649